To mimic RB1 loss-of-function alterations, we used CRISPR-Cas9 to delete RB1 in CDK4/6i sensitive MCF-7 and T47D breast cancer cells (Supplementary Fig. 1A). Here, CDK4 is linked to breast carcinoma.